|
1
|
Jayson GC, Kohn EC, Kitchener HC and
Ledermann JA: Ovarian cancer. Lancet. 384:1376–1388. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ebell MH, Culp MB and Radke TJ: A
systematic review of symptoms for the diagnosis of ovarian cancer.
Am J Prev Med. 50:384–394. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
McGuire S: World Cancer Report 2014.
Geneva, Switzerland: World Health Organization, International
Agency for Research on Cancer, WHO Press, 2015. Adv Nutr.
7:418–419. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lengyel E: ovarian cancer development and
metastasis. Am J Pathol. 177:1053–1064. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cree IA: Cancer biology. Methods Mol Biol.
731:1–11. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Holschneider CH and Berek JS: Ovarian
cancer: Epidemiology, biology, and prognostic factors. Semin Surg
Oncol. 19:3–10. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tworoger SS and Doherty JA: Epidemiologic
paradigms for progress in ovarian cancer research. Cancer Causes
Control. 28:361–364. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Siu MK, Chan HY, Kong DS, Wong ES, Wong
OG, Ngan HY, Tam KF, Zhang H, Li Z, Chan QK, et al: p21-activated
kinase 4 regulates ovarian cancer cell proliferation, migration,
and invasion and contributes to poor prognosis in patients. Proc
Natl Acad Sci USA. 107:18622–18627. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nakayama N, Nakayama K, Shamima Y,
Ishikawa M, Katagiri A, Iida K and Miyazaki K: Gene amplification
CCNE1 is related to poor survival and potential therapeutic target
in ovarian cancer. Cancer. 116:2621–2634. 2010.PubMed/NCBI
|
|
10
|
Etemadmoghadam D, George J, Cowin PA,
Cullinane C and Kansara M: Australian Ovarian Cancer Study Group,
Gorringe KL, Smyth GK and Bowtell DD: Amplicon-dependent CCNE1
expression is critical for clonogenic survival after cisplatin
treatment and is correlated with 20q11 gain in ovarian cancer. PLoS
One. 5:e154982010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ehlén Å, Brennan DJ, Nodin B, O'Connor DP,
Eberhard J, Alvarado-Kristensson M, Jeffrey IB, Manjer J,
Brändstedt J, Uhlén M, et al: Expression of the RNA-binding protein
RBM3 is associated with a favourable prognosis and cisplatin
sensitivity in epithelial ovarian cancer. J Transl Med. 8:782010.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xia Y, Chang T, Wang Y, Liu Y, Li W, Li M
and Fan HY: YAP promotes ovarian cancer cell tumorigenesis and is
indicative of a poor prognosis for ovarian cancer patients. PLoS
One. 9:e917702014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang X, George J, Deb S, Degoutin JL,
Takano EA and Fox SB: AOCS Study group, Bowtell DD and Harvey KF:
The Hippo pathway transcriptional co-activator, YAP, is an ovarian
cancer oncogene. Oncogene. 30:2810–2822. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang J, Guo X, Chang DY, Rosen DG,
Mercado-Uribe I and Liu J: CD133 expression associated with poor
prognosis in ovarian cancer. Mod Pathol. 25:456–464. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Servant N, Roméjon J, Gestraud P, La Rosa
P, Lucotte G, Lair S, Bernard V, Zeitouni B, Coffin F,
Jules-Clément G, et al: Bioinformatics for precision medicine in
oncology: Principles and application to the SHIVA clinical trial.
Front Genet. 5:1522014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Altshuler D, Daly MJ and Lander ES:
Genetic mapping in human disease. Science. 322:881–888. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen JM, Cooper DN, Chuzhanova N, Férec C
and Patrinos GP: Gene conversion: Mechanisms, evolution and human
disease. Nat Rev Genet. 8:762–775. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Segundo ES, Tsanas A and Gómez-Vilda P:
Euclidean distances as measures of speaker dissimilarity including
identical twin pairs: A forensic investigation using source and
filter voice characteristics. Forensic Sci Int. 270:25–38. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang YH, Xiao Y and Segal MR: Identifying
differentially expressed genes from microarray experiments via
statistic synthesis. Bioinformatics. 21:1084–1093. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tweedie S, Ashburner M, Falls K, Leyland
P, McQuilton P, Marygold S, Millburn G, Osumi-Sutherland D,
Schroeder A, Seal R, et al: FlyBase: Enhancing Drosophila gene
ontology annotations. Nucleic Acids Res. 37:(Database issue).
D555–D559. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lässer C, O'Neil SE, Shelke GV, Sihlbom C,
Hansson SF, Gho YS, Lundbäck B and Lötvall J: Exosomes in the nose
induce immune cell trafficking and harbour an altered protein cargo
in chronic airway inflammation. J Transl Med. 14:1812016.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Iancu OD, Colville A, Oberbeck D,
Darakjian P, Mcweeney SK and Hitzemann R: Cosplicing network
analysis of mammalian brain RNA-Seq data utilizing WGCNA and Mantel
correlations. Front Genet. 6:1742015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
RC Team: R: A language and environment for
statistical computingR Foundation for Statistical Computing.
Vienna, Austria: 2016
|
|
24
|
Beisser D, Klau GW, Dandekar T, Müller T
and Dittrich MT: BioNet: An R-Package for the functional analysis
of biological networks. Bioinformatics. 26:1129–1130. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ma X, Guo J and Sun X: DNABP:
Identification of DNA-binding proteins based on feature selection
using a random forest and predicting binding residues. PLoS One.
11:e01673452016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mikshowsky A, Weigel KA and Gianola D:
0294 Assessing genomic prediction accuracy for Holstein sires using
bootstrap aggregation sampling and leave-one-out cross validation.
J Anim Sci. 94:139–140. 2016. View Article : Google Scholar
|
|
27
|
Thomas M: ROC curve comparison of ICNARC
and POSSUM in a UK critical care unit. Br J Anaesth. 117:6672016.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
May WL: Kaplan-Meier survival
analysisEncyclopedia of Cancer. Schwab M: Springer; Berlin: pp.
1934–1937. 2011, View Article : Google Scholar
|
|
29
|
Färkkilä A, Andersson N, Bützow R, Leminen
A, Heikinheimo M, Anttonen M and Unkila-Kallio L: HER2 and GATA4
are new prognostic factors for early-stage ovarian granulosa cell
tumor-a long-term follow-up study. Cancer Med. 3:526–536. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Anttonen M, Pihlajoki M, Andersson N,
Georges A, L'hôte D, Vattulainen S, Färkkilä A1, Unkila-Kallio L,
Veitia RA and Heikinheimo M: FOXL2, GATA4, and SMAD3 co-operatively
modulate gene expression, cell viability and apoptosis in ovarian
granulosa cell tumor cells. PLoS One. 9:e855452014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cai KQ, Caslini C, Capo-Chichi CD, Slater
C, Smith ER, Wu H, Klein-Szanto AJ, Godwin AK and Xu XX: Loss of
GATA4 and GATA6 expression specifies ovarian cancer histological
subtypes and precedes neoplastic transformation of ovarian surface
epithelia. PLoS One. 4:e64542009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hendrix ND, Wu R, Kuick R, Schwartz DR,
Fearon ER and Cho KR: Fibroblast growth factor 9 has oncogenic
activity and is a downstream target of Wnt signaling in ovarian
endometrioid adenocarcinomas. Cancer Res. 66:1354–1362. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Drummond AE, Tellbach M, Dyson M and
Findlay JK: Fibroblast growth factor-9, a local regulator of
ovarian function. Endocrinology. 148:3711–3721. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Goodman MT, Lurie G, Thompson PJ, Mcduffie
KE and Carney ME: Association of two common single-nucleotide
polymorphisms in the CYP19A1 locus and ovarian cancer risk. Endocr
Relat Cancer. 15:1055–1060. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jönsson JM, Arildsen NS, Malander S,
Måsbäck A, Hartman L, Nilbert M and Hedenfalk I: Sex steroid
hormone receptor expression affects ovarian cancer survival. Transl
Oncol. 8:424–433. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Fung FK, Chan DW, Liu VW, Leung TH, Cheung
AN and Ngan HY: Increased expression of PITX2 transcription factor
contributes to ovarian cancer progression. PLoS One. 7:e370762012.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Basu M, Bhattacharya R, Ray U,
Mukhopadhyay S, Chatterjee U and Roy SS: Invasion of ovarian cancer
cells is induced byPITX2-mediated activation of TGF-β and
Activin-A. Mol Cancer. 14:1622015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Basu M and Roy SS: Wnt/β-catenin pathway
is regulated by PITX2 homeodomain protein and thus contributes to
the proliferation of human ovarian adenocarcinoma cell, SKOV-3. J
Biol Chem. 288:4355–4367. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Akiya M, Yamazaki M, Matsumoto T,
Kawashima Y, Oguri Y, Kajita S, Kijima D, Chiba R, Yokoi A,
Takahashi H, et al: Identification of LEFTY as a molecular marker
for ovarian clear cell carcinoma. Oncotarget. 8:63646–63664. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Pearce Leigh C, Near AM, Butler JL, Van
Den Berg D, Bretsky P, Conti DV, Stram DO, Pike MC, Hirschhorn JN
and Wu AH: Comprehensive evaluation of ESR2 variation and ovarian
cancer risk. Cancer Epidemiol Biomarkers Prev. 17:393–396. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Schüler S, Lattrich C, Skrzypczak M, Fehm
T, Ortmann O and Treeck O: Polymorphisms in the promoter region of
ESR2 gene and susceptibility to ovarian cancer. Gene. 546:283–287.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lourenço D, Brauner R, Lin L, De Perdigo
A, Weryha G, Muresan M, Boudjenah R, Guerra-Junior G, Maciel-Guerra
AT, Achermann JC, et al: Mutations in NR5A1 Associated with Ovarian
Insufficiency. N Engl J Med. 360:1200–1210. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kalfa N, Philibert P, Patte C, Ecochard A,
Duvillard P, Baldet P, Jaubert F, Fellous M and Sultan C:
Extinction of FOXL2 expression in aggressive ovarian granulosa cell
tumors in children. Fertil Steril. 87:896–901. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wushou A, Hou J, Zhao YJ and Shao ZM:
Twist-1 up-regulation in carcinoma correlates to poor survival. Int
J Mol Sci. 15:21621–21630. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Yin G, Alvero AB, Craveiro V, Holmberg JC,
Fu HH, Montagna MK, Yang Y, Chefetz-Menaker I, Nuti S, Rossi M, et
al: Constitutive proteasomal degradation of TWIST-1 in
epithelial-ovarian cancer stem cells impacts differentiation and
metastatic potential. Oncogene. 32:39–49. 2013. View Article : Google Scholar : PubMed/NCBI
|
